{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:53:19Z","timestamp":1787770399724,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.clon.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T19:02:12Z","timestamp":1428606132000},"page":"401-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks"],"prefix":"10.1016","volume":"27","author":[{"given":"L.","family":"Murray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Sethugavalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Robertshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-2826","authenticated-orcid":false,"given":"R.J.D.","family":"Prestwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommendations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"10.1016\/j.clon.2015.03.005_bib2","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"18","key":"10.1016\/j.clon.2015.03.005_bib4","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.clon.2015.03.005_bib5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"10.1016\/j.clon.2015.03.005_bib6","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/jnci\/87.20.1530","article-title":"Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease","volume":"87","author":"van Leeuwen","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.clon.2015.03.005_bib7","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1093\/jnci\/dji290","article-title":"Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma","volume":"97","author":"Travis","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.clon.2015.03.005_bib8","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.clon.2015.03.005_bib9","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1056\/NEJMoa064601","article-title":"Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease","volume":"357","author":"Ferme","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.clon.2015.03.005_bib10","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1200\/JCO.2003.03.023","volume":"21","author":"Engert","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.clon.2015.03.005_bib11","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1200\/JCO.2007.15.1001","article-title":"Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size","volume":"26","author":"Campbell","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.clon.2015.03.005_bib12","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2012.08.041","article-title":"Involved node radiation therapy: an effective alternative in early-stage Hodgkin lymphoma","volume":"85","author":"Maraldo","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.clon.2015.03.005_bib13","doi-asserted-by":"crossref","first-page":"4156","DOI":"10.1002\/cncr.26687","article-title":"Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy","volume":"118","author":"Campbell","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.clon.2015.03.005_bib14","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"issue":"2","key":"10.1016\/j.clon.2015.03.005_bib15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinsky","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2015.03.005_bib16","unstructured":"RAPID. http:\/\/publicukcrnorguk\/search\/StudyDetailaspx?StudyID=1299. [accessed 30.01.15]."},{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","article-title":"Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer","volume":"79","author":"Feng","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.clon.2015.03.005_bib18","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/annonc\/mdr439","article-title":"Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy","volume":"23","author":"Campbell","year":"2012","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.clon.2015.03.005_bib19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.radonc.2010.01.008","article-title":"Radiotherapy in early stage Hodgkin's lymphoma: the importance of volume and treatment position","volume":"95","author":"Reymen","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clon.2015.03.005_bib20","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1748-717X-8-22","article-title":"Hodgkin's lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms","volume":"8","author":"Cella","year":"2013","journal-title":"Radiat Oncol"},{"issue":"5","key":"10.1016\/j.clon.2015.03.005_bib21","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ijrobp.2004.12.040","article-title":"Estimation of radiation-induced cancer from three-dimensional dose distributions: concept of organ equivalent dose","volume":"61","author":"Schneider","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.clon.2015.03.005_bib22","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1118\/1.3089792","article-title":"Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula","volume":"36","author":"Schneider","year":"2009","journal-title":"Med Phys"},{"key":"10.1016\/j.clon.2015.03.005_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1742-4682-8-27","article-title":"Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy","volume":"8","author":"Schneider","year":"2011","journal-title":"Theor Biol Med Model"},{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib24","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ijrobp.2010.09.007","article-title":"Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma","volume":"80","author":"Paumier","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.clon.2015.03.005_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijrobp.2013.05.053","article-title":"Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy","volume":"87","author":"Filippi","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"12","key":"10.1016\/j.clon.2015.03.005_bib26","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.2013.51.9298","article-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"32","author":"Raemaekers","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.radonc.2013.07.013","article-title":"Reduction of the treated volume to involved node radiation therapy as part of combined modality treatment for early stage aggressive non-Hodgkin's lymphoma","volume":"109","author":"Verhappen","year":"2013","journal-title":"Radiother Oncol"},{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib28","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2011.05.054","article-title":"Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy","volume":"83","author":"Koeck","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl.","key":"10.1016\/j.clon.2015.03.005_bib29","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ijrobp.2009.04.093","article-title":"Radiation dose-volume effects in the heart","volume":"76","author":"Gagliardi","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.clon.2015.03.005_bib30","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1748-717X-7-186","article-title":"Different IMRT solutions vs. 3D-conformal radiotherapy in early stage Hodgkin's Lymphoma: dosimetric comparison and clinical considerations","volume":"7","author":"Fiandra","year":"2012","journal-title":"Radiat Oncol"},{"issue":"1","key":"10.1016\/j.clon.2015.03.005_bib31","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijrobp.2005.06.004","volume":"64","author":"Girinsky","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"10.1016\/j.clon.2015.03.005_bib32","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.3390\/ijerph9114223","article-title":"Integral dose and radiation-induced secondary malignancies: comparison between stereotactic body radiation therapy and three-dimensional conformal radiotherapy","volume":"9","author":"D'Arienzo","year":"2012","journal-title":"Int J Environ Res Public Health"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655515001065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655515001065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:41:09Z","timestamp":1760542869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655515001065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0936655515001065"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2015.03.005","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}